Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
-
Pol. Merkur. Lekarski · Feb 2011
Review[Emotional dysregulation in borderline personality disorder].
Borderline personality disorder (BDP) concerns young people, because it surfaces to emerge in early adult age and it last up to forties. Approximately 2 people out of 100 suffer from this disorder and they are mainly women. ⋯ In order to achieve the effects, very essential is to choose appropriate methods for each patients. Borderline personality disorder prognosis are far more advantageous than in any other mental disorder.
-
Pol. Merkur. Lekarski · Feb 2011
[Venous thrombosis as a complication of pacemaker implantation--own observations].
Thrombosis is a fairly rare, yet dangerous complication of pacemaker implantation. It may occur in various time intervals after the actual implantation procedure. The risk factors are as follows: inflammation or injury, vein anomalies, arrhythmia, venous stenosis. The aim of the study was to assess the risk factors for venous thrombosis, determine the interrelationship between venous thrombosis and the level of select inflammatory and pro-thrombotic factors, as well as to evaluate the actual impact of pacemaker implantation procedure within a group of patients with permanent heart stimulation system. ⋯ In patients with more than 5 thrombosis risk factors, the increased levels of IL-6, hsCRP, fibrinogen, D-dimers, TF and PAI-1 were observed. A pacemaker implantation procedure is believed to increase both thrombotic and inflammatory state in a patient for up to 7 days after the procedure. In patients prone to thrombosis, a negative correlation between the ejection fraction and the levels of hsCRP, D-dimers, TF and PAI-1 were observed.
-
Pol. Merkur. Lekarski · Jan 2011
Editorial[Novel controllers of airway obstruction in COPD patients].
For improving effectiveness of chronic obstructive pulmonary disease (COPD) therapy is necessary to influence on pharmacologic receptors in the complementary way and to reduce the dose frequency. The once-daily dose administration is an important step which may allow to enhance of patients compliance. ⋯ Moreover, some new long-acting antimuscarinic agents (LAMA) (aclidinium, glycopyrrolate) and dual-action ultra LABA+LAMA combination products are under development. The main target of therapeutic research is to produce a dimmer molecule known as M3 antagonist-beta2 agonist (MABA) bronchodilators which will open the door for a new range of combination products.
-
Pol. Merkur. Lekarski · Dec 2010
[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
The growing number of patients with head and neck cancer is a reason to search for new effective treatment strategies. Results of treatment for locally advanced squamous cell head and neck cancer with surgery and/or radiotherapy are still unsatisfactory. During last decade concomitant chemoradiotherapy became a new standard in this group of patients. The treatment method is charged of high toxicity and real therapeutic advantages are obtained by limited number of patients. Intensive clinical investigations on novel therapeutic strategies are in progress. One of them is the combination of induction chemotherapy with taxan (TPF) and concomitant chemoradiotherapy join with cisplatin. The aim of the study was to estimate the treatment tolerance and early term results with combination of induction chemotherapy with TPF and concomitant chemoradiotherapy join with cisplatin in patients with locally advanced, squamous cell carcinoma of head and neck. ⋯ Induction chemotherapy TPF and concomitant radiochemotherapy with cisplatin in patients with locally advanced head and neck cancer in III-IV clinical stages came out as the treatment of high efficacy.
-
Pol. Merkur. Lekarski · Dec 2010
Editorial[Practical applications of recombinant alpha-1-antitrypsin in medicine].
Alpha-1-antytripsin deficiency, human plasma protein belonging to serine proteinase inhibitor, is the underlying reason for causing such diseases as liver cirrhosis or pulmonary emphysema. It has been proven that alpha-1-antytripsin deficiency can be treated with replacement therapy of this protein. ⋯ Methods for the production of alpha-1-antytripsin synthesized using transgenic animals can achieve high performance while maintaining a fully functional protein structure. Obtained in this way, alpha-1-antitrypsin gives hope for the use of replacement therapy on a large scale.